Hisateru Yasui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hisateru Yasui has a total of 291 co-authors. Here are the top co-authors by number of shared publications:
- Hironaga Satake
JSMO Secretariat Division, Japanese Society of Medical Oncology, Tokyo 105-0013, Japan
35 shared publications - Takayuki Yoshino
Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
33 shared publications - Hideaki Bando
Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan
31 shared publications - Akihito Tsuji
Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Kita, Japan
30 shared publications - Yoshiaki Nakamura
Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan
30 shared publications - Eiji Oki
Department of Advanced Medicine and Innovative Technology, Kyushu University Hospital, Fukuoka, Japan
29 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (32) , 3099-3104
Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial
The randomized phase II DEEPER trial (jRCTs061180022) previously reported superior depth of response with modified 5-fluorouracil, leucovorin, oxaliplatin and irinotecan (m-FOLFOXIRI) plus cetuximab versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer (mCRC). Here, we report updated final survival outcomes and exploratory subgroup analyses focusing on RAS / BRAF wild-type and left-sided tumors. Final overall survival (OS) and progression-free survival (PFS) were analyzed in the per-protocol set (PPS) with exploratory subgroup analyses according to the presence of liver-limited disease and sex, using extended follow-up data. There were no differences in PFS and OS in the PPS. In patients with RAS / BRAF wild-type and left-sided tumors, median PFS was longer with cetuximab than with bevacizumab (14.8 v 11.9 months; hazard ratio [HR], 0.71 [95% CI, 0.52 to 0.97]; P = .029). The median OS was 50.2 months for cetuximab and 40.2 months for bevacizumab (HR, 0.74 [95% CI, 0.53 to 1.05]). In the exploratory analyses, cetuximab-based therapy was associated with longer OS in male patients (HR, 0.59; P = .016) and in patients with extrahepatic disease (HR, 0.60; P = .014). In conclusion, the DEEPER trial suggests that m-FOLFOXIRI plus cetuximab achieves superior tumor shrinkage and may be associated with favorable outcomes in selected patients with RAS / BRAF wild-type and left-sided mCRC, with exploratory signals of benefit in male patients and those with extrahepatic disease.
- 10 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (32) , 3099-3104
Open AccessLong-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial
The randomized phase II DEEPER trial (jRCTs061180022) previously reported superior depth of response with modified 5-fluorouracil, leucovorin, oxaliplatin and irinotecan (m-FOLFOXIRI) plus cetuximab versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer (mCRC). Here, we report updated final survival outcomes and exploratory subgroup analyses focusing on RAS / BRAF wild-type and left-sided tumors. Final overall survival (OS) and progression-free survival (PFS) were analyzed in the per-protocol set (PPS) with exploratory subgroup analyses according to the presence of liver-limited disease and sex, using extended follow-up data. There were no differences in PFS and OS in the PPS. In patients with RAS / BRAF wild-type and left-sided tumors, median PFS was longer with cetuximab than with bevacizumab (14.8 v 11.9 months; hazard ratio [HR], 0.71 [95% CI, 0.52 to 0.97]; P = .029). The median OS was 50.2 months for cetuximab and 40.2 months for bevacizumab (HR, 0.74 [95% CI, 0.53 to 1.05]). In the exploratory analyses, cetuximab-based therapy was associated with longer OS in male patients (HR, 0.59; P = .016) and in patients with extrahepatic disease (HR, 0.60; P = .014). In conclusion, the DEEPER trial suggests that m-FOLFOXIRI plus cetuximab achieves superior tumor shrinkage and may be associated with favorable outcomes in selected patients with RAS / BRAF wild-type and left-sided mCRC, with exploratory signals of benefit in male patients and those with extrahepatic disease.
- Open Access
- 10 September 2026
- Published by MDPI AG in Gastroenterology Insights
- Vol. 17 (3) , 52
Efficacy and Safety of Reduced-Dose Chemotherapy Plus Nivolumab in Elderly Advanced Gastric Cancer
Background/Objective: The standard first-line treatment for advanced or recurrent gastric cancer (AGC) includes chemotherapy combined with an immune checkpoint inhibitor or zolbetuximab, but delivering fluoropyrimidine-platinum chemotherapy at standard doses can be difficult in elderly patients. Method: We retrospectively collected clinical data from 70 patients aged 70 years or older with AGC who received first-line chemotherapy plus nivolumab between July 2017 and December 2024. Patients who started treatment without dose reduction were classified as the normal group, whereas those who received a reduced starting dose of fluoropyrimidine and/or platinum were classified as the reduced group. Results: Fifty patients were assigned to the reduced group and 20 to the normal group. The reduced group was older, more frequently received SOX, and more often had PD-L1 combined positive scores ≥ 1. Objective response rate, disease control rate, progression-free survival, and overall survival did not differ significantly between the groups. In contrast, grade ≥ 3 adverse events and any-grade infections were more frequent in the normal group. Conclusions: These findings suggest that reduced-dose chemotherapy plus nivolumab may be an effective and less toxic first-line option for elderly patients with AGC.
- 10 September 2026
- Published by MDPI AG in Gastroenterology Insights
- Vol. 17 (3) , 52
Open AccessEfficacy and Safety of Reduced-Dose Chemotherapy Plus Nivolumab in Elderly Advanced Gastric Cancer
Background/Objective: The standard first-line treatment for advanced or recurrent gastric cancer (AGC) includes chemotherapy combined with an immune checkpoint inhibitor or zolbetuximab, but delivering fluoropyrimidine-platinum chemotherapy at standard doses can be difficult in elderly patients. Method: We retrospectively collected clinical data from 70 patients aged 70 years or older with AGC who received first-line chemotherapy plus nivolumab between July 2017 and December 2024. Patients who started treatment without dose reduction were classified as the normal group, whereas those who received a reduced starting dose of fluoropyrimidine and/or platinum were classified as the reduced group. Results: Fifty patients were assigned to the reduced group and 20 to the normal group. The reduced group was older, more frequently received SOX, and more often had PD-L1 combined positive scores ≥ 1. Objective response rate, disease control rate, progression-free survival, and overall survival did not differ significantly between the groups. In contrast, grade ≥ 3 adverse events and any-grade infections were more frequent in the normal group. Conclusions: These findings suggest that reduced-dose chemotherapy plus nivolumab may be an effective and less toxic first-line option for elderly patients with AGC.
- Open Access
- 9 September 2026
- Published by Springer Nature in Communications Medicine
Longitudinal ctDNA profiling to guide anti-EGFR rechallenge in metastatic colorectal cancer: a prospective single-arm phase II trial
- 9 September 2026
- Published by Springer Nature in Communications Medicine
Open AccessLongitudinal ctDNA profiling to guide anti-EGFR rechallenge in metastatic colorectal cancer: a prospective single-arm phase II trial
- Open Access
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (7) , e2600237
Identification of a Novel GOLGB1-RET Fusion in Papillary Thyroid Cancer With a Durable Response to Selpercatinib
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (7) , e2600237
Open AccessIdentification of a Novel GOLGB1-RET Fusion in Papillary Thyroid Cancer With a Durable Response to Selpercatinib
- Open Access
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (3) , e2500971
Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy
PURPOSE: Advanced esophageal squamous cell carcinoma (ESCC) has a poor prognosis, and current treatments provide limited survival benefits. This study aimed to identify prognostic biomarkers and therapeutic targets by genomic profiling of advanced ESCC using circulating tumor DNA (ctDNA). METHODS: The SCRUM-MONSTAR GOZILA study is a nationwide, plasma-based molecular profiling project using Guardant360, involving 31 core cancer institutions in Japan. We evaluated the genomic landscape of advanced ESCC and investigated associations between specific alterations and overall survival (OS). The correlation between blood tumor mutation burden (bTMB) and clinical outcomes in patients with PD-1 inhibitors was also assessed using multiple cutoff values (2, 4, 6, 8, and 10 mutations/Mb). RESULTS: Among 313 patients, alterations predominantly consisted of single nucleotide variants (SNVs, 68.9%) and copy number alterations (20.7%). TP 53 was the most frequent alterations (88.5%), followed by PIK3CA (36.4%), NFE2L2 (24.3%), CCND1 (22.4%), and EGFR (20.1%). Amplifications in PIK3CA , FGFR1 , CCND1 , and EGFR , as well as mutations in NFE2L2 , FGFR1 , and RB1 were associated with worse OS (any P < .05). Multivariable analysis confirmed mutations in NFE2L2 or FGFR1 and amplifications in EGFR or PIK3CA as independent poor prognostic factors (all P < .05). In 142 patients treated with PD-1 inhibitors, no significant differences in objective response rate or progression-free survival were observed at different bTMB cutoff values (all P > .1). CONCLUSION: ctDNA analysis identified key genomic alterations linked to poor outcomes in advanced ESCC, revealing potential prognostic biomarkers and therapeutic targets. In contrast, bTMB did not show predictive value for the efficacy of PD-1 inhibitors in this study.
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (3) , e2500971
Open AccessPrognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy
PURPOSE: Advanced esophageal squamous cell carcinoma (ESCC) has a poor prognosis, and current treatments provide limited survival benefits. This study aimed to identify prognostic biomarkers and therapeutic targets by genomic profiling of advanced ESCC using circulating tumor DNA (ctDNA). METHODS: The SCRUM-MONSTAR GOZILA study is a nationwide, plasma-based molecular profiling project using Guardant360, involving 31 core cancer institutions in Japan. We evaluated the genomic landscape of advanced ESCC and investigated associations between specific alterations and overall survival (OS). The correlation between blood tumor mutation burden (bTMB) and clinical outcomes in patients with PD-1 inhibitors was also assessed using multiple cutoff values (2, 4, 6, 8, and 10 mutations/Mb). RESULTS: Among 313 patients, alterations predominantly consisted of single nucleotide variants (SNVs, 68.9%) and copy number alterations (20.7%). TP 53 was the most frequent alterations (88.5%), followed by PIK3CA (36.4%), NFE2L2 (24.3%), CCND1 (22.4%), and EGFR (20.1%). Amplifications in PIK3CA , FGFR1 , CCND1 , and EGFR , as well as mutations in NFE2L2 , FGFR1 , and RB1 were associated with worse OS (any P < .05). Multivariable analysis confirmed mutations in NFE2L2 or FGFR1 and amplifications in EGFR or PIK3CA as independent poor prognostic factors (all P < .05). In 142 patients treated with PD-1 inhibitors, no significant differences in objective response rate or progression-free survival were observed at different bTMB cutoff values (all P > .1). CONCLUSION: ctDNA analysis identified key genomic alterations linked to poor outcomes in advanced ESCC, revealing potential prognostic biomarkers and therapeutic targets. In contrast, bTMB did not show predictive value for the efficacy of PD-1 inhibitors in this study.
- Open Access
- 27 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Association of ICI efficacy with ASV based on treatment.
- 27 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Association of ICI efficacy with ASV based on treatment.
- Open Access
- 27 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
The ALDEx2 analysis of flora according to PFS of ICI treatment.
- 27 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
The ALDEx2 analysis of flora according to PFS of ICI treatment.
- Open Access
- 27 May 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
α diversity of gut microbiome according to clinical features and cancer types. A, Diagram depicting the selection of the MONSTAR-SCREEN cohorts. ECOG, Eastern Cooperative Oncology Group; PS, performance status. B, Definition of oral bacteria. A total of 10 genera were defined as oral bacteria in this study from the data of the article by Atarashi and colleagues. C, Violin plot of α diversity based on ASV counts in feces according to concomitant medication use. A two-sided P value was calculated with the Welch t test. D, Violin plot of α diversity by ASV count in feces according to lifestyle habit. A two-sided P value was calculated with the Welch t test. For the number of defecations per day, the Kruskal–Wallis test was applied. LABB, lactic acid bacteria beverage.
- 27 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
α diversity of gut microbiome according to clinical features and cancer types. A, Diagram depicting the selection of the MONSTAR-SCREEN cohorts. ECOG, Eastern Cooperative Oncology Group; PS, performance status. B, Definition of oral bacteria. A total of 10 genera were defined as oral bacteria in this study from the data of the article by Atarashi and colleagues. C, Violin plot of α diversity based on ASV counts in feces according to concomitant medication use. A two-sided P value was calculated with the Welch t test. D, Violin plot of α diversity by ASV count in feces according to lifestyle habit. A two-sided P value was calculated with the Welch t test. For the number of defecations per day, the Kruskal–Wallis test was applied. LABB, lactic acid bacteria beverage.